HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan“) is pleased to announce that it intends to complete an offering of […]
Tag: Innocan Pharma Corporation
Innocan Pharma Granted First Patent in India for its Liposomal CBD Injection
Innovative Chronic Pain Treatment Receives IP Protection in India’s $55 Billion Pharmaceutical Market HERZLIYA, Israel and CALGARY, AB, Feb. 18, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), […]
Innocan Pharma’s Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone
HERZLIYA, Israel and CALGARY, AB, Jan. 29, 2025 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that […]
Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs
HERZLIYA, Israel and CALGARY, AB, Nov. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to report positive […]
Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New York Also Announces Relaunch of Updated Website for Enhanced Investor Experience USA – English Israel – English
HERZLIYA, Israel and Calgary, AB, Oct. 16, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in chronic pain management via Liposomal CBD drug products, is pleased […]
العربية
简体中文
Dansk
Nederlands
English
Esperanto
Suomi
Français
Deutsch
עִבְרִית
हिन्दी
Íslenska
Italiano
日本語
한국어
Монгол
नेपाली
Norsk bokmål
Português
Русский
Samoan
Afsoomaali
Español
Svenska
ไทย
Türkçe
Українська
יידיש
Zulu